Lite Strategy, Inc.

Listed Company
LITSCIK 0001262104NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Jun 30
Period
FY 2025
Revenue
$0
Net Income
$-16.00M
Total Assets
$18.29M
Equity
$16.93M
Shares Out
34.03M
Op. Cash Flow
$-20.84M
LITS$0.99−68.91% · past 10 monthsDBEQ Basic
Daily closing prices

Business

Lite Strategy, Inc. (formerly MEI Pharma) is a pharmaceutical company developing novel cancer therapies through clinical and pre-clinical programs. The company's pipeline includes voruciclib, an oral CDK9 inhibitor in early-stage development, and zandelisib, a PI3Kδ inhibitor in pre-clinical assessment, both evaluated in combination with standard-of-care treatments. Following a strategic alternatives review, the company implemented a digital-asset treasury strategy and is assessing pre-clinical drug development activities. The company operates globally but does not manufacture; it relies on contract manufacturers and strategic partnerships.

Summary from 10-K filed 2025-09-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts
ConceptTrend
FY 2025
2025-06-30
FY 2024
2024-06-30
FY 2023
2023-06-30
FY 2022
2022-06-30
FY 2021
2021-06-30
Revenues065494135
Research and development417528669
General and administrative1423333124
Impairment of long-lived assets0110
Total operating expenses17518611695
(Loss) income from operations−1715−37−75−60
Interest and dividend income133284,000510,000
Gain on disposition of a non-financial asset500,0000
Other expense, net−16,000−41,000−22,000−6,000486,000
Total other income, net2352119
Net (loss) income−1618−32−54−41
Basic (per share)−2.392.67−4.78−8.75−0.37
Diluted (per share)−2.392.67−4.78−9.99−0.6
Basic (shares)7776113
Diluted (shares)7776114

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Lite Strategy, Inc.'s CIK number?

Lite Strategy, Inc.'s SEC CIK number is 0001262104 (1262104). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Lite Strategy, Inc.'s SEC filings?

All of Lite Strategy, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Lite Strategy, Inc. last report earnings?

Lite Strategy, Inc. (LITS) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-220697). This is Lite Strategy, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Lite Strategy, Inc.'s most recent earnings 8-K?

Lite Strategy, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001193125-26-220697. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Lite Strategy, Inc.'s latest earnings 8-K →
Look up any company's CIK number →